• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

High-Level Negotiations On LDC Pharma IP Waiver Extension At WTO

30/10/2015 by Catherine Saez, Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Negotiations have been ongoing at the World Trade Organization over the extension of a waiver allowing least-developed countries not to grant or enforce intellectual property rights on pharmaceutical products.

The issue was unsuccessfully debated at the last meeting of the World Trade Organization intellectual property committee earlier this month. Since then, discussions have been ongoing between the Least Developed Countries (LDCs) Group and the United States, apparently the last WTO member to resist the LDCs’ request.

The discussions on the issue have reached ambassador level. According to sources, ambassadors from Nepal, Bangladesh and Uganda met with the US ambassador at the WTO on 28 October without finding consensus. They were expected to meet again yesterday, the sources said.

At issue is the impending expiration on 1 January 2016 of a waiver for LDCs to enforce IP rights on pharmaceutical products under the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). LDCs have requested an open-ended extension to apply to countries as long as they hold LDC status. Meanwhile, another general TRIPS waiver exists for LDCs until 2021.

According to some sources, the US had proposed a 10-year extension in the negotiations, which was refused by the LDC Group.

According to an LDC source, the purpose of the ambassadorial meetings is to find a solution that would take into account the interests of the LDCs and the concerns of the US.

The US position, according to the source, is grounded in the fact that TRIPS Article 66.1 stipulates that the Council for the TRIPS “shall upon duly motivated request by a least-developed country Member, accord extensions of this period.” So the US does not see the point in granting an indefinite extension, the source said.

The LDC benefit from a general IP waiver, running until 2021 but they would like to keep a separate exception for pharmaceutical products.

According to the source, LDCs see no interest in dragging out the conversation any longer and would like to see a swift solution found.

Once that solution has been found, the TRIPS Council is expected to resume so that a decision can be formally adopted.

On 16 October, the WTO Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) – which met on 15-16 October – was suspended for lack of agreement on the subject of the extension (IPW, WTO/TRIPS, 17 October 2015).

The LDC request has been supported by numerous organisations and countries.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Catherine Saez may be reached at csaez@ip-watch.ch.

Creative Commons License"High-Level Negotiations On LDC Pharma IP Waiver Extension At WTO" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, Enforcement, English, Health & IP, Human Rights, Patents/Designs/Trade Secrets, WTO/TRIPS

Trackbacks

  1. WTO Decision on Least Developed Country (LDC) Drug Patent Waiver | Don't trade our lives away says:
    04/11/2015 at 7:22 am

    […] High-Level Negotiations On LDC Pharma IP Waiver Extension At WTO […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.